Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad039Source: DataRank Database

Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy is a research paper published in The Journal of Infectious Diseases (2023). On theSindex it has a DataRank of 0. It has been cited 32 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access32 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)OA: greenTopics (9)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (28)

Ronald J. Bosch ORCID,Hanna Mar,Gregory M. Laird ORCID,Elias K. Halvas ORCID,Laura Hovind

Live enrichment

PubMed:21097893

National Institute of Allergy and Infectious Diseases

Grant: UM1AI068636

National Institute of Allergy and Infectious Diseases

Grant: UM1AI106701

National Institute of Allergy and Infectious Diseases

Grant: UM1AI068634

National Institute of Allergy and Infectious Diseases

Grant: UM1AI069481

Small Business Innovation Research

Grant: R43AI142866

Small Business Innovation Research

Grant: R44AI124996

NIH Cooperative Agreement

Grant: U24AI143502

I4C Martin Delaney Collaboratory

Grant: UM1 AI126603

Beat-HIV Collaboratory

Grant: UM1 AI126620

National Science Foundation Small Business Innovation Research

Grant: 1738428

SBIR Phase II: Development and Optimization of a New Molecular Test to quantify Latent HIV-1 in Samples from HIV-1 Infected Individuals.

Harvard University Center for AIDS Research

Grant: P30 AI060354

AIDS Clinical Trials Group

Grant: 2 UMAI069412

National Institutes of Health

Grant: 6UM1AI069481-17

Seattle-Lausanne Clinical Trials Unit

National Institutes of Health

Grant: 1R43AI142866-01

Development of a quantitative assay for intact HIV DNA measures in tissue

National Institutes of Health

Grant: 3UM1AI106701-12S1

AIDS Clinical Trial Group Laboratory Center

National Institutes of Health

Grant: 5R44AI124996-03

A Novel Test to Measure Latent Virus in HIV-1 Infected Patients

National Institutes of Health

Grant: 5UM1AI068634-09

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)

National Institutes of Health

Grant: 3UM1AI068636-19SC

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

National Institutes of Health

Grant: 5UM1AI126620-05

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

greenLicense: OUP Standard Publication Reuse

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10474937/pdf/jiad039.pdf

publisherhttps://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad039/49406460/jiad039.pdf

publisherhttps://academic.oup.com/jid/article-pdf/227/12/1376/51335260/jiad039.pdf

https://doi.org/10.1093/infdis/jiad039

https://pubmed.ncbi.nlm.nih.gov/36763044

Fields of Study

0303 health sciences03 medical and health sciences

Keywords

CD4-Positive T-LymphocytesProvirusesAnti-Retroviral AgentsDNA, ViralHIV-1HumansHIV Infections

Sustainable Development Goals

SDG 3: 3. Good health

Related Papers (10)

Immune correlates of HIV-1 reservoir cell decline in early-treated infants

N/A

0.953DataRank · unranked

Cell Reports(2022)

co-cited

10.1016/j.celrep.2022.111126

Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy

N/A

0.751DataRank · unranked

The Journal of Infectious Diseases(2020)

co-citedsame journal

10.1093/infdis/jiaa532

Differential decay of intact and defective proviral DNA in HIV-1–infected individuals on suppressive antiretroviral therapy

JCI Insight(2020)

co-cited

10.1172/jci.insight.132997

Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission

Current Opinion in HIV and AIDS(2024)

co-cited

10.1097/coh.0000000000000839

Distinct viral reservoirs and immune signatures in individuals on long-term antiretroviral therapy with perinatally acquired HIV-1

Cell Reports Medicine(2025)

co-cited

10.1016/j.xcrm.2025.102150

Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses

Cell(2022)

co-cited

10.1016/j.cell.2021.12.011

HIV reservoir quantification using cross-subtype multiplex ddPCR

iScience(2021)

co-cited

10.1016/j.isci.2021.103615

ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study

N/A

0.405DataRank · unranked

The Lancet HIV(2025)

co-cited

10.1016/s2352-3018(25)00189-4

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy

Journal of Clinical Investigation(2023)

co-cited

10.1172/jci171554

Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy

N/A

0.657DataRank · unranked

The Journal of Infectious Diseases(2020)

co-citedsame journal

10.1093/infdis/jiaa718